Global Dermatomyositis Treatment Market, Treatment Type (Corticosteroids, Immunosuppressive Agents, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Dermatomyositis Treatment Market Analysis and Size
The global dermatomyositis treatment market is expected to witness significant growth during the forecast period. As per the records of the Rare Disease Organization, the rate of occurrence of dermatomyositis is projected to be about 9.63 cases per million people worldwide. Cancer-related dermatomyositis occurs more frequently in people between the age group of 40 to 50 years. Athough there is no characteristic cancer type or site, experts specify that underlying cancers can most frequently grow in the testes, the ovaries, the lungs, the GI tract, the breasts, or some lymphoid tissues. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global dermatomyositis treatment market in the forecast period 2022-2029. The expected CAGR of global dermatomyositis treatment market is tend to be around 5.1% in the mentioned forecast period. The market was valued at USD 743.2 million in 2021, and it would grow upto USD 1106.44 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Dermatomyositis Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment Type (Corticosteroids, Immunosuppressive Agents, Others), Route of Administration (Oral, Topical, Others),End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Endo International Inc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Cipla Inc (India), Dr Reddy's Laboratories Ltd (India), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc (U.S.), Zydus Group (India), Lupin (India), Amorphex Therapeutics Holdings, Inc (U.S.), Bausch Health Companies Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Dermatomyositis is a rare inflammatory skin disorders that is typically characterized by muscle weakness and a severe skin rash. It is mainly caused by either viral infection of the tissues of skeletal muscle or autoimmune reaction. Symptoms may vary broadly from patient to patient. Deformities in the muscles may initiate with weakness and pain in the muscles of the thighs, the hips, the upper arms, and the trunk. The muscles may become sore, tender, and stiff and eventually express signs of degeneration.
Global Dermatomyositis Treatment Market Dynamics
Drivers
- Increase in Autoimmune Disorders
As per the National Institute of Environmental Health Sciences, more than 80 autoimmune diseases have been identified namely diabetes (type 1), multiple sclerosis, rheumatoid arthritis, lupus, and celiac disease. Increase in the occurrence of these diseases drives the global dermatomyositosis market. This boosts the growth of the market.
- Rising Demand for Oral Drugs
Oral drugs is projected to boost the market growth. The segment is expected to speed up the global market as most products are accessible in capsule and tablet form and it is a very convenient route of administration.
Opportunities
- Rising Incidence of Dermatomyositis
As per the records of Rare Disease Organization, the rate of occurrence of dermatomyositis is projected to be around 9.63 cases per million people worldwide. In children, dermatomyositis symptoms usually occur between 5 and 15 years of age. Juvenile dermatomyositis affects approximately one in every 100,000 children. Dermatomyositis is two times more common in women than in men.
- Increasing Demand for Retail Pharmacies
The rise in the number of dermatomyositis therapeutics delivered through retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create opportunities for the market growth. In addition to this, patients choose retail pharmacies for purchasing drugs, as these are easily available.
Restraints/Challenges
- Limited Studies and Surveys
There are very limited studies and surveys that is hampering the growth of the market. Only a minimal amount of data are available with respect to the studies. A few studies mainly focused on groups from a single hospital wherein only a limited number of patients are observed. Thus, this hampers the growth of the market.
- High Cost
The huge expenditure associated with dermatomyositis medications hamper the market growth. This disease involves treatment with corticosteroids, different immunosuppressive agents which demands huge expenditure. This acts as a major hindrance for the market.
This global dermatomyositis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global dermatomyositis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Dermatomyositis Treatment Market
COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period. It has been observed that COVID-19 can induce a systemic inflammatory response, and its clinical appearances are different. Recently, it has been stated that COVID-19 patients may develop myositis and interstitial pulmonary disease that is similar to dermatomyositis (DM).
In the post-pandemic era, the market is expected to rise because of the availability of varied treatment options such as anti-inflammatory therapy that may benefit patients. Other than that, glucocorticoids, antagonists are also helpful.
Global Dermatomyositis Treatment Market Scope
The global dermatomyositis treatment market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Immunosuppressive Agents
- Corticosteroids
- Others
Route of Administration
- Oral
- Topical
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Dermatomyositis Treatment Market Regional Analysis/Insights
The global dermatomyositis treatment market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global dermatomyositis treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global dermatomyositis treatment market throughout the forecasted period due to the high disposable income and advanced healthcare facilities.
Asia-Pacific dominates the market due to presence of rapidly developing economies such as China and India in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Dermatomyositis Treatment Market Share Analysis
The global dermatomyositis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global dermatomyositis treatment market
Key players operating in the global dermatomyositis treatment market include:
- Novartis AG (Switzerland)
- Endo International Inc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Glenmark Pharmaceuticals Ltd (India)
- Cipla Inc (India)
- Dr Reddy's Laboratories Ltd (India)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc (U.S.)
- Zydus Group (India)
- Lupin (India)
- Amorphex Therapeutics Holdings, Inc (U.S.)
- Bausch Health Companies Inc. (U.S.)
SKU-